Chiara Wertz is currently employed as a Clinical Research Associate at St. Anna Kinderkrebsforschung. Prior to this, Chiara worked at Amgen in the role of Medical Affairs Oncology/Hematology. Chiara also gained experience as a Pharmacist in Training at Rosenapotheke München. Chiara obtained their Staatsexamen in Pharmazie from The Philipp University of Marburg and completed an exchange semester in Pharmacy at the University of Eastern Finland.
This person is not in the org chart
This person is not in any offices
St. Anna Children's Cancer Research Institute (CCRI)
The St. Anna Children's Cancer Research Institute (St Anna CCRI), located in the center of Vienna, the world's most livable city and one of Europe's most important places for biomedical research and life sciences, is an internationally renowned multidisciplinary research institution with the aim to develop and optimize diagnostic, prognostic, and therapeutic strategies for the treatment of children and adolescents with cancer. To achieve this goal we combine basic research with translational and clinical research and focus on the specific characteristics of childhood tumor diseases in order to provide young patients with the best possible and most innovative therapies. Dedicated research groups in the fields of tumor genomics and epigenomics, immunology, molecular biology, cell biology, bioinformatics and clinical research are working together to harmonize scientific findings with the clinical needs of physicians to ultimately improve the wellbeing of our patients. Through close cooperation between clinic and research, the CCRI provides an ideal environment for cutting-edge research and its translation into clinical practice. To achieve our ultimate goal of advancing the well-being of patients, the CCRI constantly pushes scientific boundaries and strongly promotes close collaboration and exchange with external institutions like the Medical University of Vienna, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) and the Institute of Molecular Pathology (IMP).